Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)
| Market Cap | $378.82M-68.6% |
| Revenue (ttm) | $274.88M+86.8% |
| Net Income | -$83.00M+69.8% |
| EPS | -$1.03+73.0% |
| Shares Out | 81.29M |
| PE Ratio | n/a |
| Forward PE | 7.64 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,330,427 |
| Open | $5.14 |
| Previous Close | $5.08 |
| Day's Range | $4.62 - $5.14 |
| 52-Week Range | $4.62 - $18.31 |
| Beta | 0.50 |
| Analysts | Buy |
| Price Target | $16.50(+254.08%) |
| Earnings Date | Feb 25, 2027 |
About PHAT
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
Next catalysts
- Feb 25, 2027Earnings report
$PHAT stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in PHAT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by PHAT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
PHAT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
PHAT Revenue by Segment
| Product revenue, net | $84.72M | 82.34% |
| Stock-based compensation | $18.17M | 17.66% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New PHAT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to PHAT from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in PHAT
| VTIVanguard Morningstar Total Stock Market ETF | $9.08M |
| IWMiShares Russell 2000 ETF | $6.55M |
| XPHState Street SPDR S&P Pharmaceuticals ETF | $4.29M |
| VXFVanguard Extended Market ETF | $3.85M |
| IBBiShares Biotechnology ETF | $2.02M |
| IWNiShares Russell 2000 Value ETF | $1.69M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from PHAT’s recent data — informational, not investment advice
What’s Behind the Score
News check: Mixed coverage with awareness campaign offset by significant stock decline; lacks concrete business catalysts or analyst actions.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| SURI | Simplify Propel Opportunities ETF | 2.03% |
| XPH | State Street SPDR S&P Pharmaceuticals ETF | 0.97% |
| BBP | Virtus Biotech ETF | 0.78% |
| PQSG | PGIM ETF Trust - PGIM QMA Strategic Alpha Small-Cap Growth ETF | 0.17% |
| PILL | Direxion Daily Pharmaceutical & Medical Bull 3X ETF | 0.14% |
| IWC | iShares Micro-Cap ETF | 0.08% |
| IHE | iShares U.S. Pharmaceuticals ETF | 0.07% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.03% |
| IBB | iShares Biotechnology ETF | 0.02% |
| BIB | ProShares Ultra Nasdaq Biotechnology | 0.02% |
| VHT | Vanguard Health Care ETF | 0.01% |
| FHLC | Fidelity MSCI Health Care Index ETF | 0.00% |
Weight is the stock’s share of each fund’s holdings.
